The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

May 15, 2020 • By Vania Lin, MD, MPH, & Leah Krull, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Discussion

A CT of the chest without contrast showed multiple nodular and coalescing opacities involving the bilateral lungs diffusely, with more extensive involvement of the bibasilar regions.

A CT of the chest without contrast showed multiple nodular and coalescing opacities involving the bilateral lungs diffusely, with more extensive involvement of the bibasilar regions.

Dermatomyositis encompasses a host of musculoskeletal and cutaneous symptoms, the latter of which are often hetero­geneous in presentation. It is thought that differing serological responses, as reflected via various antibody markers, may represent differing immune responses, even unique phenotypes, with associated keratinocyte damage, which may explain the heterogeneity of presentation.4,5

You Might Also Like
  • A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
  • Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis
  • Case Report: A Patient Develops Scleroderma Renal Crisis
Explore This Issue
May 2020

MDA5, a receptor that binds with RNA and triggers a type I interferon response in infectious and inflammatory processes, was discovered in 2002 and has since become a point of interest in the study of autoimmune processes.6 Among patients with DM, certain features are strongly associated with anti-MDA5, including the absence of myositis and the presence of palmar papules, peri­ungual, digital and elbow cutaneous ulcers, and rapidly progressive ILD, suggesting a unique phenotype that may pose its own treatment challenge.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Initial treatment of DM often comprises anti-malarials, but there is no consensus on first-line therapy.3,7 Further, symptoms frequently require more aggressive treatment and a combination of multiple medications to achieve adequate control. Common additional agents include corticosteroids, calcineurin inhibitors (e.g., cyclosporine, tacrolimus), steroid-sparing immunosuppressants (e.g., methotrexate, azathioprine, cyclophosphamide, MMF) and intravenous immunoglobulin.8 Despite the use of these agents, symptoms often remain refractory.

Among patients with dermatomyositis, certain features are strongly associated with anti-MDA5, including the absence of myositis & the presence of palmar papules, periungual, digital & elbow cutaneous ulcers, & rapidly progressive ILD, suggesting a unique phenotype that may pose its own treatment challenge.

Recent advancements in biologics have introduced new treatment possibilities for DM. Therapies under investigation may be divided into those targeting B and T cells, and those targeting cytokines. Among these agents, rituximab, lenabasum, tofacitinib, apremilast, anakinra and tocilizumab have been promising in their effects on skin symptoms.3,9–13

In our patient with concurrent CADM and RA, agents that address both disease processes are of particular interest; the presence of ILD, common among CADM patients, adds further consideration to treatment choice. Rituximab, tofacitinib and tocilizumab, well studied in the treatment of RA, are of increasing interest in the treatment of CADM, given promising results in addressing skin symptoms.14

Regarding ILD, a suggested treatment approach is clinical evaluation and pulmonary function tests every three to six months, in addition to: 1) a combination of steroids and the choice of rituximab, cyclophosphamide or a calcineurin inhibitor for acute or severe pulmonary disease; or 2) a combination of steroids and the choice of MMF or azathioprine for chronic or milder ILD.15

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

These considerations ultimately led to our chosen treatment regimen of hydroxychloroquine, prednisone, MMF and rituximab.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Clinically Amyotrophic Dermatomyositis (CADM), combination therapy, interstitial lung disease (ILD)Issue: May 2020

You Might Also Like:
  • A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
  • Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis
  • Case Report: A Patient Develops Scleroderma Renal Crisis
  • Case Report: Cardiac Tamponade in a Rheumatoid Arthritis Patient

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.